Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.
about
Streptococcus pneumoniae biofilm formation and dispersion during colonization and diseaseIn vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in ItalyThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemBronchiectasis in Children: Current Concepts in Immunology and MicrobiologyMechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration.Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic modelBactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.Absence of evidence for enhanced benefit of antibiotic therapy on recurrent acute rhinosinusitis episodes: a systematic review of the evidence base.No evidence for distinguishing bacterial from viral acute rhinosinusitis using fever and facial/dental pain: a systematic review of the evidence base.Antimicrobial resistance in livestock.Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.Mucosal immunization against respiratory bacterial pathogens.Antimicrobial resistance of bacterial agents of the upper respiratory tract in South Indian population.Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.Appropriate use of antibiotics: focus on acute otitis media.Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humansA randomized controlled study of 5 and 10 days treatment with phenoxymethylpenicillin for pharyngotonsillitis caused by streptococcus group A - a protocol studyPneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo.Novel approaches to developing new antibiotics for bacterial infections.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Pharmacodynamics of antimicrobials: treatment optimisation.Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatmeManipulating virulence factor availability can have complex consequences for infections.Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis.Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial.High prevalence of nasal carriage of β-lactamase-negative ampicillin-resistant Haemophilus influenzae in healthy children in Korea.Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid.Predicting the clinical efficacy of generic formulations of ceftriaxone.Bioadhesive controlled metronidazole release matrix based on chitosan and xanthan gum.influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strainCorrelations between Microbiological Outcomes and Clinical Responses in Patients with Severe Pneumonia.Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections.Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin.Costs associated with the management of overactive bladder and related comorbidities.An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.
P2860
Q28082440-FF455164-BC80-4E12-96E6-6443F9964E17Q28209003-DC819751-4795-4320-8D6D-ADA0B8BB6AF2Q28289744-11041E1E-6D9B-4646-87F9-EC9939696B35Q33734772-687D2438-7D51-4ADE-B94B-5726064872C0Q34498620-37D5B5DD-151C-4FC9-86E9-43C61D1B2A96Q34631455-9AC445C5-FB7E-4B22-A480-F7A646FF4A68Q34820573-43D92D7C-FCA4-4250-B4EF-9DD65E606744Q34882995-81A8EFCD-64E8-4219-88B6-0E2F06720292Q34883537-4776A955-406B-47E3-A16E-086F4667E4E0Q34996726-EB8B9F6C-2A5E-4CBE-BDC9-1095776922FBQ35072365-D895906F-7800-4016-B6A7-141C3B3B783AQ35095235-B7A1B137-6135-42F7-9E8F-B38D58C4E642Q35165999-FD731DBE-1F16-4432-9452-92E32B11DA06Q35623339-4746124A-7BE4-406A-AF20-B6F317906017Q35664680-A76EEBF3-A5D4-4556-B914-67FFAF5BE20DQ35692693-625CDB5D-71DC-42D9-9832-A0069897E9EEQ35760716-0B2D9DBF-5378-4221-A75E-5A6BF023095CQ35917371-ED5F65E3-7693-4F29-A584-C3E27E95E711Q35964560-F77CCE05-3707-4074-B461-6007E55EC011Q36047112-CA13E18B-9928-4913-871B-0EE21236D0ABQ36130284-F827E857-385B-40B7-84E0-D65915D6DCADQ36211192-0736E52C-8B90-4FE0-A26E-F1DC8D02E55DQ36358643-159294EF-2995-4F86-9282-BF4FDF06AB19Q36505518-32CDCB6C-DD22-42F6-98F6-9840F53D9ABCQ36544935-34BC259D-3164-4A79-B42D-062CA064C391Q37489324-E04CE91E-DC29-462E-8F5C-70A12514C24AQ37539878-21C5CCB9-1814-4172-8A10-76663D581266Q38100143-BF12666E-F400-492C-B290-D7C66B93AF28Q38434088-F65DDE25-B0C4-4CC2-A089-C8A8A2585997Q40038000-14CAB34F-97FD-4089-8250-775AB9CF826EQ40252977-FF9B0C03-E38F-4DD1-B3B9-BF166AEF5E04Q40369183-36E17781-4CB7-4616-A035-38BD5BEF3C38Q41042375-A7CFDD0A-974A-4973-BDC7-0B76D06A6671Q42012067-772E57D1-827C-4F41-B745-4F4C6AD444A5Q42097160-4A03D72E-B62D-485D-B3CD-0B3755FD619AQ42582994-E00CAEA1-1C94-4760-96D7-1BC52E388604Q43207762-C65AA9D4-432C-46FD-899B-4081878020E4Q44089196-DD2BB913-A1DD-444E-B5E3-684380A24A5BQ44200515-1857CE92-B52B-4C15-843B-0D1AD541C6E4Q44510164-C65018E2-E64A-44CA-8FEE-89A4511BD379
P2860
Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Evidence to support the ration ...... aim of antimicrobial therapy.
@ast
Evidence to support the ration ...... aim of antimicrobial therapy.
@en
Evidence to support the ration ...... aim of antimicrobial therapy.
@nl
type
label
Evidence to support the ration ...... aim of antimicrobial therapy.
@ast
Evidence to support the ration ...... aim of antimicrobial therapy.
@en
Evidence to support the ration ...... aim of antimicrobial therapy.
@nl
prefLabel
Evidence to support the ration ...... aim of antimicrobial therapy.
@ast
Evidence to support the ration ...... aim of antimicrobial therapy.
@en
Evidence to support the ration ...... aim of antimicrobial therapy.
@nl
P2093
P356
P1476
Evidence to support the ration ...... aim of antimicrobial therapy.
@en
P2093
P304
P356
10.1093/JAC/47.2.129
P407
P577
2001-02-01T00:00:00Z